Contact Us
  • Choose License Type

Global Chronic Kidney Disease Drugs Market, by Drug Type (ACE Inhibitors, B-blockers, Calcium Channel Blockers, Loop Diuretics, Erythropoiesis-stimulating Agents (ESAs), Phosphate Binders, and Others), by Route of Administration (Oral, Intravenous, and Subcutaneous), by Patient Type (Dialysis and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), is estimated to be valued at US$ 12,328.2 million in 2020 and is expected to exhibit a CAGR of 4.0% over the forecast period (2020-2027), as highlighted in a new report published by Coherent Market Insights.

The increasing prevalence of chronic kidney disease is expected to drive the market growth over the forecast period. For instance, according to the Centers for Disease Control and Prevention (CDC) estimations 2019, the chronic kidney disease is more common in people of age 65 years or above and around 125,000 people in the U.S. started treatment for end-stage kidney disease (ESKD) and over 726,000 (2 in every 1,000 people) in 2018 were on dialysis or were living with a kidney transplant.

Chronic kidney disease is the progressive loss of kidney function over a period of several years. As kidney failure advances to further stages, and the organ’s function is severely impaired, dangerous levels of waste and fluid can rapidly build up in the body. Early detection can help prevent the progression of kidney disease to kidney failure. Heart disease is the major cause of death for people with CKD. Treatment is aimed at stopping or slowing down the progression of the disease – this is usually done by controlling its underlying cause. ACE Inhibitors, B-blockers, Calcium Channel Blockers, and Erythropoiesis-stimulating Agents (ESAs) are some of the major drug class used in the treatment of chronic kidney disease or its underlying cause.

Global Chronic Kidney Disease Drugs Market – Impact of Coronavirus (Covid-19) Pandemic

The COVID-19 pandemic has impacted the global economy and in turn, the chronic kidney disease drugs market. Quarantine, traveling constraints, and social distancing measures are likely to lead to a steep decline in business and consumer spending until the end of the second quarter of 2020. Moreover, the COVID-19 pandemic has drastically affected clinical trials. Many trials have paused enrollment and researchers are facing multiple challenges associated with setting up remote visits, and performing laboratory, and other study assessments.

Browse 44 Market Data Tables and 39 Figures spread through 206 Pages and in-depth TOC on “Chronic Kidney Disease Drugs Market”- Global Forecast to 2027, by Drug Type (ACE Inhibitors, B-Blockers, Calcium Channel Blockers, Loop Diuretics, Erythropoiesis-Stimulating Agents (ESAs), Phosphate Binders, and Others), by Route of Administration (Oral, Intravenous, and Subcutaneous), by Patient Type (Dialysis and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa),

To know the latest trends and insights prevalent in the global Chronic Kidney Disease Drugs market, click the link below:

https://www.coherentmarketinsights.com/market-insight/chronic-kidney-disease-drugs-market-1713

Furthermore, product approvals and launches for the treatment of chronic kidney disease are expected to drive the market growth over the forecast period. For instance, in November 2018, Kissei Pharmaceutical Co., Ltd. launched P-TOL Granules (250 mg and 500 mg) tablets indicated for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis. Moreover, in June 2019, Reata Pharmaceuticals, Inc. received the orphan drug designation from the U.S. Food and Drug Administration (FDA) for bardoxolone methyl (bardoxolone) indicated for the treatment of autosomal dominant polycystic kidney disease (ADPKD).

Key Takeaways of the Global Chronic Kidney Disease Drugs Market:

  • The global chronic kidney disease drugs market is expected to exhibit a CAGR of 4.0% during the forecast period, owing to growing prevalence of chronic kidney disease and increasing approvals & launches of novel drugs for the treatment of chronic kidney disease. For instance, according to Lancet data, prevalence of chronic kidney disease in Western Europe was estimated at 41,976,625 patients in 2017.
  • Among drug type, erythropoiesis-stimulating agents (ESAs) segment is estimated to hold a dominant position in the global chronic kidney disease drugs market in 2020, owing to recent launches of novel products by key players. For instance, For instance, in May 2018, Pfizer Inc. received approval from the U.S. Food and Drug Administration (FDA) for Retacrit, a biosimilar to Epogen and Procrit (epoetin alfa) by Amgen Inc.
  • On the basis of route of administration, intravenous segment is estimated to hold a dominant position in the global chronic kidney disease drugs market in 2020 due to increasing regulatory approval for intravenous drugs, faster action, and robust pipeline of intravenous products. For instance, For instance, in February 2017, Amgen, Inc. received approval from the U.S. Food and Drug Administration (FDA) for Parsabiv (etelcalcetide), indicated for the treatment of secondary hyperparathyroidism (sHPT) in adult patients with chronic kidney disease (CKD) on hemodialysis
  • In terms of patient type, dialysis segment is estimated to account for major market share in 2020 due to rise in number of patients suffering from end-stage renal disease, growing number of dialysis procedures & treatment centers, and increasing research activities seeking treatment options for dialysis patients. For instance, According to 2018 annual report of the U.S Renal Data System (USRDS), around 750,000 patients per year in the U.S. are affected by kidney failure, which is also called end stage renal disease (ESRD). Moreover, according to the same source, around 2 million people worldwide suffer from ESRD every year.
  • Among distribution channel, hospital pharmacies segment dominated the global chronic kidney disease drugs market in 2020, owing to increasing number of patient admission in hospitals due to chronic kidney disease, and partnerships & agreements of hospitals with specialty pharmacies services providers. For instance, according to one of the articles published in WebMD LLC., in 2018, emergency department visits due to end-stage renal disease (ESRD) increased to an average of 3 per patient per year in the U.S.
  • Among regions, North America is estimated to hold largest market share in the global chronic kidney disease drugs market in 2020, owing to higher prevalence of chronic kidney disease and end-stage renal disease, and presence of higher number of patients with high blood pressure and diabetes in the region, which are leading causes of chronic kidney disease. For instance, according to CDC, high blood pressure and diabetes are leading causes of chronic kidney disease. Currently, approximately 1 in 3 adults with diabetes and 1 in 5 adults with high blood pressure might have chronic kidney disease in the U.S.
  • Key players operating in the global chronic kidney disease drugs market include Amgen, Inc., Teva Pharmaceutical Industries Ltd., Pfizer Inc., AstraZeneca Plc, Hoffmann La Roche Ltd., Sanofi S.A., Kissei Pharmaceutical Co. Ltd., AbbVie Inc., Reata Pharmaceuticals, Inc., GlaxoSmithKline Plc, and Ardelyx, Inc.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner